المؤلفون: Pirkko-Liisa Kellokumpu-Lehtinen, Françoise Rothé, Michail Ignatiadis, Heikki Joensuu, Martine Piccart, David Venet, Christos Sotiriou, Delphine Vincent, Carsten Denkert, Nicolas Sirtaine, Debora Fumagalli, Sherene Loi, Roberto Salgado, Sibylle Loibl, Amir Sonnenblick, Patrick Neven, Sylvain Brohée, Christine Desmedt, Gert Van den Eynden

المساهمون: Lääketieteen yksikkö - School of Medicine, University of Tampere, Clinicum, Heikki Joensuu / Principal Investigator, Department of Oncology

المصدر: BMC Medicine
BMC medicine, 13 (1

مصطلحات موضوعية: PROGNOSIS, Receptor, ErbB-2, Estrogen receptor, STAT3, ACTIVATION, PATHWAY, ADJUVANT CHEMOTHERAPY, Breast cancer, Trastuzumab, Prospective Studies, Phosphorylation, Trastuzumab resistance, skin and connective tissue diseases, Medicine(all), TYROSINE PHOSPHORYLATION, biology, Reverse phase protein lysate microarray, General Medicine, Sciences bio-médicales et agricoles, Middle Aged, TUMORS, 3. Good health, DNA-Binding Proteins, FinHer, Female, Life Sciences & Biomedicine, Signal Transduction, Research Article, medicine.drug, EXPRESSION, Adult, Randomised trial, 3122 Cancers, Antineoplastic Agents, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Medicine, General & Internal, Phosphorylated STAT3, Syöpätaudit - Cancers, General & Internal Medicine, HER2, medicine, Humans, PTEN, neoplasms, Aged, Science & Technology, business.industry, Gene signature, medicine.disease, Drug Resistance, Neoplasm, biology.protein, STAT protein, Cancer research, Neoplasm Recurrence, Local, business, Transcription Factors

وصف الملف: Electronic; fulltext; 1 full-text file(s): application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::430eb9469863c7e570e64158ce76f08b
https://doi.org/10.1186/s12916-015-0416-2